Oruka Therapeutics (ORKA) Cash & Current Investments (2010 - 2026)

Oruka Therapeutics has reported Cash & Current Investments for 17 years, with the latest figure at $384.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 39.35% year-over-year to $384.7 million; the trailing twelve-month figure through Mar 2026 stood at $384.7 million (down 39.35% YoY), and the FY2025 full-year result was $767.5 million, up 104.32% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $384.7 million, down from $767.5 million in the prior quarter.
• The five-year high for Cash & Current Investments was $767.5 million in Q4 2025, with the low at $33.3 million in Q2 2024.
• Average Cash & Current Investments over 5 years is $214.6 million, with a median of $46.4 million recorded in 2022.
• Year-over-year, Cash & Current Investments surged 1666.86% in 2025 and tumbled 39.35% in 2026.
• Tracing ORKA's Cash & Current Investments over 5 years: stood at $42.4 million in 2022, then declined by 11.81% to $37.4 million in 2023, then surged by 903.57% to $375.6 million in 2024, then jumped by 104.32% to $767.5 million in 2025, then slumped by 49.87% to $384.7 million in 2026.
• The last three Cash & Current Investments figures came in at $384.7 million (Q1 2026), $767.5 million (Q4 2025), and $346.9 million (Q3 2025), per Business Quant data.

Peer Comparison